137 results on '"Blatný, Jan"'
Search Results
2. Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)
3. Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders Database
4. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
5. Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
6. A novel thrombocytopenia‐4‐causing CYCS gene variant decreases caspase activity: Three‐generation study.
7. Incidence of inhibitor development in PUPs with severe Haemophilia A in the CEE region between 2005 and 2015
8. Moving towards Normalization of haemostasis and health equity: Evolving treatment goals for haemophilia A.
9. Teenagers and Adolescents with Hemophilia–Need for a Specific Approach.
10. Czech and Slovak Diamond-Blackfan Anemia (DBA) Registry update: Clinical data and novel causative genetic lesions
11. Efficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage
12. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review
13. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
14. Rationale for the Potential Use of Recombinant Activated Factor VII in Severe Post-Partum Hemorrhage.
15. Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regions.
16. Real‐world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe
17. https://www.prolekare.cz/en/journals/transfusion-and-haematology-today/2023-1-15/recommendations-for-thrombotic-risk-stratification-and-targeted-thromboprophylaxis-in-women-during-assisted-reproduction-133823
18. sj-docx-1-tah-10.1177_20406207231165857 – Supplemental material for Considerations for shared decision management in previously untreated patients with hemophilia A or B
19. Considerations for shared decision management in previously untreated patients with hemophilia A or B
20. Inherited coagulation disorders
21. Disseminated intravascular coagulation in children
22. Hemorrhagic disease of the newborn caused by vitamin K deficiency
23. Cerebrovascular Complications of COVID-19 Disease in Children: A Single-Center Case Series
24. The Czech National Diamond-Blackfan Anemia Registry: Clinical data and ribosomal protein mutations update
25. Sharing datasets of the COVID-19 epidemic in the Czech Republic
26. Control Centre for Intensive Care as a Tool for Effective Coordination, Real-Time Monitoring, and Strategic Planning During the COVID-19 Pandemic
27. Prophylaxis in children with haemophilia in an evolving treatment landscape
28. Changes in haemocoagulation in healthy volunteers after a 1-hour thrombotripsy using a diagnostic 2–4 MHz transcranial probe
29. Control Centre for Intensive Care as a Tool for Effective Coordination, Real-Time Monitoring, and Strategic Planning During the COVID-19 Pandemic (Preprint)
30. Consensual guidelines of the Czech National Haemophilia Programme (CNHP) for the diagnosis and treatment of patients with congenital haemophilia and FVIII/ FIX inhibitors
31. Fibrinogen Nový Jičín and Praha II: Cases of hereditary Aα 16 Arg → Cys and Aα 16 Arg → His dysfibrinogenemia
32. Consensual guidelines of the Czech National Haemophilia Programme (CNHP) for the dia gnosis and treatment of patients with haemophilia, 3rd edition, year 2021
33. Sharing Datasets of the COVID-19 Pandemic in the Czech Republic (Preprint)
34. Social support and resilience in persons with severe haemophilia: An interpretative phenomenological analysis
35. Analysis of von Willebrand Disease in the South Moravian Population (Czech Republic): Results from the BRNO-VWD Study
36. European principles of inhibitor management in patients with haemophilia.
37. Konsensuální doporučení ČNHP (Českého národního hemofilického programu) pro diagnostiku a léčbu pacientů s vrozenou hemofilií a s inhibitorem FVIII/FIX
38. The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany
39. The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany.
40. The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany
41. The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany
42. Novel homozygous fibrinogen Aα chain truncation causes severe afibrinogenemia with life threatening complications in a two-year-old boy
43. Patients with inhibitors: diagnostic and therapeutic challenges, multidisciplinary approach
44. Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015
45. Partnering to change the world for people with haemophilia: 6thHaemophilia Global Summit, Prague, Czech Republic, 24-26thSeptember 2015
46. Data Coming out of the Human Inhibitor PUP Study (HIPS) Reveal 4 Subgroups of Patients with Distinct Antibody Signatures
47. A Practical, One Clinic Visit, Population Pharmacokinetic (PK) Protocol for Generation of PK Profiles in Subjects with Severe Hemophilia a
48. The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH
49. Safety and efficacy of recombinant activated factor VII in nonhemophilia children with severe or life-threatening bleeding
50. Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.